Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03652389 · ClinicalTrials.gov registry record · NA
i-Matter: Investigating an mHealth Texting Tool for Embedding Patient-reported Data Into Diabetes Management
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 246
- Enrollment target
NCT03652389 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 246 participants.
The verdict
NCT03652389, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 246 participants
- Enrollment target
Study Summary
This study will integrate a technology-based patient-reported outcome (PRO) system \[herein MJS DIABETES\] that incorporates patients' perspective of their disease and functional status into the management of type 2 diabetes (T2D) in primary care practices. MJS DIABETES is an innovative mobile platform that utilizes text-messaging to capture patients' self-reported PROs in real-time; enhance patient engagement through data-driven feedback and motivational messages; and create dynamic visualizations of the PROs that can be shared in printed reports, and integrated into the EHR; thus making it actionable for patients and their PCPs. Using a mixed-methods design, this study will be conducted in 2 phases: 1) a formative phase, using the evidence-based user-centered design approach; and 2) a clinical-efficacy phase. For the formative phase, a qualitative research method will be used to: a) adapt MJS to the needs of PCPs and T2D patients; b) integrate MJS DIABETES into the EHR system, the primary care practice and the lives of patients with T2D; and c) evaluate the usability of MJS DIABETES in a subset of T2D patients and their PCPs in order to optimize the tool's performance and workflow integration. For the clinical efficacy phase, a randomized control trial will be used to identify the efficacy of MJS DIABETES versus Usual Care (UC) on reduction HbA1c at 12-months, among 282 patients with T2D who receive care in safety-net practices.
Interventions
- BEHAVIORAL MJS Diabetes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2018-12-18 |
| Est. Completion | 2024-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03652389
The ClinicalTrials.gov registry entry for NCT03652389 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MJS Diabetes is the first listed.
NCT03652389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03652389 about?
NCT03652389 is a clinical study titled "i-Matter: Investigating an mHealth Texting Tool for Embedding Patient-reported Data Into Diabetes Management". This study will integrate a technology-based patient-reported outcome (PRO) system \[herein MJS DIABETES\] that incorporates patients' perspective of their disease and functional status into the management of type 2 diabetes (T2D) in primary care practices. MJS DIABETES is an innovative mobile platf...
What is the current status of trial NCT03652389?
This trial is currently completed. It is a NA study. The enrollment target is 246 participants. The study started on 2018-12-18. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT03652389?
The interventions under investigation include: MJS Diabetes (BEHAVIORAL).
Who is sponsoring clinical trial NCT03652389?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.